+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05909618

Phase 2 Study of Crizanlizumab Alone or With Nivolumab for Advanced Glioblastoma and Metastatic Melanoma with Brain Metastases

Led by Sheba Medical Center · Updated on 2025-07-22

33

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying crizanlizumab alone and in combination with nivolumab to evaluate their safety, tolerance, and effectiveness in patients with advanced glioblastoma GB who have exhausted standard treatments, patients with metastatic brain melanoma MBM, and patients newly diagnosed with unmethylated GB. This phase III open-label study involves patients who have failed prior therapies or are not candidates for maintenance temozolomide therapy due to MGMT promoter status. The study includes three groups Cohort 1 with metastatic melanoma brain metastases after failed immunotherapy Cohort 2 with recurrent or progressing GB after radiation and temozolomide and Cohort 3 with newly diagnosed unmethylated GB after radiation. Treatments vary by cohort, with crizanlizumab dosed at 5 mgkg alone or with nivolumab every 2 to 4 weeks, continuing until disease progression, unacceptable side effects, or completion of up to 2 years or 12 months depending on the group. Participants will be monitored weekly at first, then every 2 to 4 weeks for safety and tolerability. Brain MRI scans will be done every 8 weeks to assess tumor response, with additional CT scans for metastatic melanoma. Quality of life and cognitive function will be regularly assessed, and blood, tissue, and cerebrospinal fluid samples collected for research on drug effects and biomarkers. Follow-up continues after treatment completion to evaluate long-term outcomes.

CONDITIONS

Brief Title

Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases

Research Team

R

Ronnie Shapira Frommer, Dr

M

Meital Bar

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here